Phase IV study of safety and efficacy of docetaxel in combination with prednisone in advanced hormone refractory prostate cancer treatment

Trial Profile

Phase IV study of safety and efficacy of docetaxel in combination with prednisone in advanced hormone refractory prostate cancer treatment

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2011

At a glance

  • Drugs Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 May 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-001873-91).
    • 21 Apr 2008 The expected completion date for this trial is now 1 Oct 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top